NCT01678027

Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication

Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,838 (actual)
• Sponsor: National Cancer Center, Korea · Other Government
• Sex: All
• Age: 40 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study evaluate whether treatment of Helicobacter pylori infection reduces the incidence of gastric cancer in subjects with family history of gastric cancer.

Detailed description

Helicobacter pylori infection is associated with gastric cancer in epidemiological studies. However, it is still unknown whether H. pylori eradication is useful and required to prevent gastric cancer. Gastric cancer risk is increased in family members of gastric cancer patient. Though there is no direct evidence that H. pylori infection is a risk factor for gastric cancer in family members of gastric cancer, current European guideline recommends H. pylori eradication in first-degree relatives of gastric cancer patients. In this study, the investigators will evaluate whether H. pylori eradication can reduce gastric cancer risk in the first-degree family members of gastric cancer patients.

Conditions

• Gastric Cancer
• Helicobacter Pylori Infection
• Family Members

Interventions

Type	Name	Description
DRUG	Placebo	Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
DRUG	LAC triple therapy	Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.

Timeline

• Start date: 2004-11-01
• Primary completion: 2018-12-01
• Completion: 2035-12-01
• First posted: 2012-09-03
• Last updated: 2023-11-09

Locations

1 site across 1 country: South Korea